Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Omicron Inactivated COVID-19 Vaccine Booster
NCT05374954Phase 3Unknown
- Sponsor
- China National Biotec Group
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Omicron Inactivated COVID-19 Vaccine (Vero Cell) in coronavirus disease 2019 (COVID-19) (28 arms), sponsored by China National Biotec Group. Primary endpoints: Geometric Mean Titer of neutralizing antibody against Omicron SARS-CoV-2 at 28 days, Four-fold increase rate of neutralizing antibody against Omicron SARS-CoV-2 at 28 days and 1 more. Status: unknown.
02
Drugs
Omicron Inactivated COVID-19 Vaccine (Vero Cell)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05374954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374954.